SCHEMBL9302206

SCHEMBL9302206

Cn1cccc1-c1[c]cccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCSK9 Q8NBP7 1/20 0.43
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 3/20 0.39
GAA P10253 1/20 0.39
CYP2A6 P11509 1/20 0.38
CYP2A13 Q16696 1/20 0.38
NPC1 O15118 1/20 0.38
RECQL P46063 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TSHR P16473 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
INMT O95050 1/20 0.33
NQO2 P16083 1/20 0.32
TRIM24 O15164 1/20 0.32
TRIM33 Q9UPN9 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1225875 0.74 PARP1 (0.35) ALDH1A1KDM4ENPC1TSHRMAPT
SCHEMBL197196 0.72 PCSK9 (0.60) PCSK9ALDH1A1KDM4EGAACYP2A6
SCHEMBL6797908 0.72
SCHEMBL115447 0.69 CYP3A4 (0.33) SMN1; SMN2ALOX15
SCHEMBL715058 0.69 PCSK9 (0.49) PCSK9ALDH1A1KDM4EGAANPC1
SCHEMBL18706157 0.69 COMT (0.42) ALDH1A1KDM4ENPC1LMNAMAPT
SCHEMBL8487798 0.68 FLT3 (0.33) ALDH1A1TSHRSMN1; SMN2
SCHEMBL1521829 0.68 BRD4 (0.44) KDM4ENPC1HSD17B10ESR1
SCHEMBL6444709 0.67 PCSK9 (0.73) PCSK9ALDH1A1KDM4EGAACYP2A6
SCHEMBL11758704 0.67 KMT2A (0.56) ALDH1A1KDM4ENPC1RECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2023-11-16 US claimed
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2023-10-31 US claimed
EP-3692023-B1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST BIOTHERAPEUTICS INC (KR) 2023-05-17 EP claimed
EP-3927705-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1st Biotherapeutics, Inc. (KR) 2021-12-29 EP claimed
EP-3927706-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS 1st Biotherapeutics, Inc. (KR) 2021-12-29 EP claimed
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2021-11-11 US claimed
CN-113454081-A Imidazopyridinyl compounds and their use for the treatment of proliferative diseases 第一生物治疗股份有限公司 2021-09-28 CN claimed
CN-113454082-A Imidazopyridinyl compounds and their use for the treatment of neurodegenerative diseases 第一生物治疗股份有限公司 2021-09-28 CN claimed
US-10968188-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2021-04-06 US claimed
US-20200270222-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2020-08-27 US claimed
US-20200270246-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2020-08-27 US claimed
EP-3692023-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1st Biotherapeutics, Inc. (KR) 2020-08-12 EP claimed
CN-111315727-A Benzothiazole compounds and methods of using the same for treating neurodegenerative diseases 第一生物治疗股份有限公司 2020-06-19 CN claimed
US-10669246-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2020-06-02 US claimed
WO-2019070093-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2019-04-11 WO claimed
US-20190100500-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2019-04-04 US claimed
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2023-11-16 US disclosed
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2023-10-31 US disclosed
US-20190100500-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2019-04-04 US disclosed
US-5364617-A Protection from solar radiation, chelate with iron in body and reduce its ability to catalyze formation of oxygen free radicals THE PROCTER & GAMBLE COMPANY (US) 1994-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT PCSK9 903/4885ALDH1A1 2344/4885KDM4E 3156/4885
US-20190100500-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS ABL2, ABL1, MAPT PCSK9 1987/4885ALDH1A1 2101/4885KDM4E 2026/4885
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders SMN1; SMN2, SNCA, HTT PCSK9 903/4885ALDH1A1 2344/4885KDM4E 3156/4885
US-10669246-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders ABL2, ABL1, MAPT PCSK9 1987/4885ALDH1A1 2101/4885KDM4E 2026/4885
US-10968188-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders ABL2, ABL1, MAPT PCSK9 1987/4885ALDH1A1 2101/4885KDM4E 2026/4885
US-20200270246-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT PCSK9 903/4885ALDH1A1 2344/4885KDM4E 3156/4885
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT PCSK9 903/4885ALDH1A1 2344/4885KDM4E 3156/4885
US-20200270222-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS ABL2, ABL1, MAPT PCSK9 1987/4885ALDH1A1 2101/4885KDM4E 2026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.